Multiple Sclerosis Therapy
Reports from University of Innsbruck, Department of Neurology add new data to research in multiple sclerosis therapy
Published in Drug Law Weekly, February 20th, 2007
Investigators publish new data in the report "Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial." According to recent research from Innsbruck, Austria, "About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Delta(9)-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS)."
"The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-02-20)
More Articles from Drug Law Weekly
- Abdominal Aortic Aneurysms
Stanford researchers launch study on effects of exercise on abdominal aneurysms - Business Update
Heska announces sale of allergy patent portfolio - Finance
Adherex announces equity offering up to US$25 million - Finance
Avalon Pharmaceuticals closes $10 million in private placement of common stock - Finance
Haemacure Corp. completes $12.5 million private placement - Legal Issues
Angiotech wins patent infringement case in the Netherlands - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
